209 related articles for article (PubMed ID: 36407959)
1. Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C.
Stephenson Clarke JR; Douglas LR; Duriez PJ; Balourdas DI; Joerger AC; Khadiullina R; Bulatov E; Baud MGJ
ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1169-1180. PubMed ID: 36407959
[TBL] [Abstract][Full Text] [Related]
2. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines.
Baud MGJ; Bauer MR; Verduci L; Dingler FA; Patel KJ; Horil Roy D; Joerger AC; Fersht AR
Eur J Med Chem; 2018 May; 152():101-114. PubMed ID: 29702446
[TBL] [Abstract][Full Text] [Related]
3. Anticancer therapeutic strategies for targeting mutant p53-Y220C.
Chasov V; Davletshin D; Gilyazova E; Mirgayazova R; Kudriaeva A; Khadiullina R; Yuan Y; Bulatov E
J Biomed Res; 2024 May; 38(3):222-232. PubMed ID: 38738269
[TBL] [Abstract][Full Text] [Related]
4. An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.
Bromley D; Bauer MR; Fersht AR; Daggett V
Protein Eng Des Sel; 2016 Sep; 29(9):377-90. PubMed ID: 27503952
[TBL] [Abstract][Full Text] [Related]
5. Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs.
Bauer MR; Jones RN; Baud MG; Wilcken R; Boeckler FM; Fersht AR; Joerger AC; Spencer J
ACS Chem Biol; 2016 Aug; 11(8):2265-74. PubMed ID: 27267810
[TBL] [Abstract][Full Text] [Related]
6. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.
Boeckler FM; Joerger AC; Jaggi G; Rutherford TJ; Veprintsev DB; Fersht AR
Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10360-5. PubMed ID: 18650397
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional metallochaperone modifications for targeting subsite cavities in mutant p53-Y220C.
Miller JJ; Kwan K; Blanchet A; Orvain C; Mellitzer G; Smith J; Lento C; Nouchikian L; Omoregbee-Leichnitz S; Sabatou M; Wilson D; Gaiddon C; Storr T
J Inorg Biochem; 2023 May; 242():112164. PubMed ID: 36871418
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer.
Miller JJ; Orvain C; Jozi S; Clarke RM; Smith JR; Blanchet A; Gaiddon C; Warren JJ; Storr T
Chemistry; 2018 Dec; 24(67):17734-17742. PubMed ID: 30230059
[TBL] [Abstract][Full Text] [Related]
9. A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C.
Bauer MR; Jones RN; Tareque RK; Springett B; Dingler FA; Verduci L; Patel KJ; Fersht AR; Joerger AC; Spencer J
Future Med Chem; 2019 Oct; 11(19):2491-2504. PubMed ID: 31633398
[No Abstract] [Full Text] [Related]
10. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.
Basse N; Kaar JL; Settanni G; Joerger AC; Rutherford TJ; Fersht AR
Chem Biol; 2010 Jan; 17(1):46-56. PubMed ID: 20142040
[TBL] [Abstract][Full Text] [Related]
11. Wild type p53 function in p53
Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373
[TBL] [Abstract][Full Text] [Related]
12. First-order rate-determining aggregation mechanism of p53 and its implications.
Wang G; Fersht AR
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13590-5. PubMed ID: 22869710
[TBL] [Abstract][Full Text] [Related]
13. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics.
Garg S; Singh J; Verma SR
J Mol Model; 2023 Jan; 29(2):55. PubMed ID: 36700982
[TBL] [Abstract][Full Text] [Related]
14. Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm.
Bauer MR; Krämer A; Settanni G; Jones RN; Ni X; Khan Tareque R; Fersht AR; Spencer J; Joerger AC
ACS Chem Biol; 2020 Mar; 15(3):657-668. PubMed ID: 31990523
[TBL] [Abstract][Full Text] [Related]
15. Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach.
Rauf SM; Endou A; Takaba H; Miyamoto A
Protein J; 2013 Jan; 32(1):68-74. PubMed ID: 23315175
[TBL] [Abstract][Full Text] [Related]
16. Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53
Radhakrishnan N; Dhanjal JK; Sari AN; Ishida Y; Terao K; Kaul SC; Sundar D; Wadhwa R
Discov Oncol; 2021 Dec; 12(1):64. PubMed ID: 35201513
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators.
Balourdas DI; Markl AM; Krämer A; Settanni G; Joerger AC
Cell Death Dis; 2024 Jun; 15(6):408. PubMed ID: 38862470
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening of p53 mutants reveals Y220S as an additional rescue drug target for PhiKan083 with higher binding characteristics.
Raghavan V; Agrahari M; Gowda DK
Comput Biol Chem; 2019 Jun; 80():398-408. PubMed ID: 31128451
[TBL] [Abstract][Full Text] [Related]
19. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening.
Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M
J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488
[TBL] [Abstract][Full Text] [Related]
20. AI-powered discovery of a novel p53-Y220C reactivator.
Zhou S; Chai D; Wang X; Neeli P; Yu X; Davtyan A; Young K; Li Y
Front Oncol; 2023; 13():1229696. PubMed ID: 37593097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
